Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $794.76M
• Dividend Yield: N/A
• Average Volume (3M): 17.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: 11070.12%
• EPS Growth: 32.07%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 333,934,400
• 10 Day Avg. Volume: 12,504,614
• 30 Day Avg. Volume: 17,114,534
• PEG Ratio: -1.02
• Price to Book (P/B): 11.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.76
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 1.74
• Enterprise Value/Gross Profit: 21.32
• Enterprise Value/Ebitda: -0.58
• 1Y Price Target: $10.73
• Price Target Upside: 364.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 48 Neutral
• Price Target: $2.50 ▲(8.23%Upside)

Iovance Biotherapeutics shows promising revenue growth and shareholder support but faces profitability and operational challenges. Mixed technical indicators and valuation concerns further affect the score. Positive earnings call highlights are counterbalanced by operational issues.

Positive Factors

Clinical Efficacy

Efficacy in additional solid tumor indications could be just what the doctor ordered.

Durable Responses

Key opinion leaders were generally impressed by long-term survival and the durable responses are seen as a major achievement for AMTAGVI.

Market Potential

AMTAGVI has significant market and value generating potential and the positive results and KOL conversations at ASCO '25 help reaffirm that position.

Negative Factors

Competitive Landscape

The increasingly competitive landscape in advanced melanoma poses challenges for AMTAGVI, with emerging therapies aiming to raise the bar on efficacy and safety.

Financial Performance

The stock has experienced negative pressure due to the lower than expected AMTAGVI revenue and downward revised financial guidance.

Market Momentum

AMTAGVI has faced periods of uneven momentum since its launch, indicating challenges in establishing a strong foothold in the market.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and potential commercialization of its proprietary TIL therapy products. The company's revenue model is based on bringing these therapies to market either independently or through partnerships with other pharmaceutical companies. Iovance may earn income through licensing agreements, collaboration with other firms, and potential future sales of approved therapies. Additionally, significant partnerships or alliances with larger pharmaceutical companies can provide funding, milestone payments, and royalties, contributing to its revenue streams.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics shows significant revenue growth, but remains unprofitable with a negative net income and cash flow challenges. Strong equity position with low leverage, yet operational inefficiencies and sustained losses pose long-term concerns.

Income Statement

Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.

Cash Flow

The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
212.68M	164.07M	1.19M	0.00	0.00	0.00
	Gross Profit
40.83M	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
	EBIT
-398.78M	-395.28M	-460.56M	-398.88M	-342.70M	-261.94M
	EBITDA
-354.01M	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
	Net Income Common Stockholders
-375.36M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
359.71M	323.78M	279.87M	471.85M	596.00M	629.44M
	Total Assets
966.74M	910.43M	780.35M	663.98M	777.33M	768.46M
	Total Debt
53.72M	58.26M	75.86M	84.45M	71.53M	51.66M
	Net Debt
-117.95M	-57.43M	-39.03M	-147.28M	-6.70M	-15.67M
	Total Liabilities
198.88M	200.02M	195.74M	164.34M	155.67M	111.96M
	Stockholders Equity
767.87M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow		Free Cash Flow
-347.50M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
	Operating Cash Flow
-334.39M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
	Investing Cash Flow
30.96M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
	Financing Cash Flow
340.40M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Neutral. The current price of 2.31 is above the 20-day moving average (MA) of 1.90, below the 50-day MA of 2.60, and below the 200-day MA of 6.45, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 53.53 is Neutral, neither overbought nor oversold. The STOCH value of 79.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	64 Neutral	$1.31B	―	-49.41%	―	4.86%	10.13%
PCRX	59 Neutral	$1.13B	―	-12.27%	―	3.08%	-247.82%
ARDX	57 Neutral	$885.24M	―	-36.26%	―	127.33%	21.31%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
IOVA	48 Neutral	$794.76M	―	-51.85%	―	11070.12%	32.07%
SNDX	48 Neutral	$937.92M	―	-93.70%	―	―	-25.83%
ETNB	42 Neutral	$1.50B	―	-69.30%	―	―	-68.13%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Approves Key Proposals at Annual Meeting

On June 10, 2025, Iovance Biotherapeutics held its Annual Meeting of Stockholders virtually, where stockholders voted on five key proposals. These included the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the accounting firm, and amendments to increase shares in the equity incentive and employee stock purchase plans. All proposals were approved, reflecting strong shareholder support and potentially enhancing the company’s operational flexibility and strategic initiatives.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.